Cyclooxygenase inhibitors are often prescribed to relieve severe ischemic leg
pain in critical ischemic limb patients. Prescription of high doses of
aspirin and selective
cyclooxygenase-2 inhibitors is reported to increase cardiovascular events through suppression of the vasodilative
prostanoid prostaglandin I(2) in endothelium. Here, we evaluated the influence of
aspirin and
etodolac, a selective
cyclooxygenase-2 inhibitor, on neovascularization using a murine
ischemia hind limb model. C57BL/6J mice were treated with
aspirin or
etodolac for twenty-eight days after induction of
ischemia. We exploited a concentration of the agents that suppressed
cyclooxygenase activity efficiently, especially in
prostaglandin I(2) production. Recovery of limb blood perfusion and capillary density in ischemic limbs was significantly suppressed by
etodolac treatment when compared to the
aspirin treated group and untreated group. Production of 6-keto
prostaglandin F(1alpha) and
prostaglandin E(2) was lower in the
aspirin treated group when compared with the
etodolac-treated group. Also, these concentrations were lower in both treatment groups compared with the untreated group. Immunohistochemical analysis suggested
cyclooxygenase-2 was expressed in endothelium but not in inflammatory cells in ischemic tissue from the acute to chronic phase.
Cyclooxygenase-1 was expressed strongly in inflammatory cells in the acute phase. Furthermore, bone marrow-derived mononuclear
cell transplantation improved neovascularization, whereas
aspirin and
etodolac did not inhibit these effects. Production of
arachidonic acid metabolites by transplanted cells was independent of the improvement of neovascularization. In conclusion,
cyclooxygenase-2 inhibition reduces
ischemia-induced neovascularization.